COMPASS Pathways plc (NASDAQ: CMPS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
15.19
+0.19+1.27%
News
Up 1.3% — COMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit Transcript (seekingalpha.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 12.58% | Shs Outstand | 134.92M | Perf Week | 5.85% |
| Market Cap | 2.05B | Forward P/E | - | EPS next Y | -1.66 | Insider Trans | 0.00% | Shs Float | 129.50M | Perf Month | 8.42% |
| Enterprise Value | 1.67B | PEG | - | EPS next Q | -0.36 | Inst Own | - | Short Float | 11.17% | Perf Quarter | 21.23% |
| Income | -288.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 4.13 | Perf Half Y | 165.10% |
| Sales | 0.00 | P/B | 24.11 | EPS next Y | 26.18% | ROA | -78.12% | Short Interest | 14.47M | Perf YTD | 120.14% |
| Book/sh | 0.63 | P/C | 4.73 | EPS next 5Y | - | ROE | -398.21% | 52W High | 15.87 -4.28% | Perf Year | 201.39% |
| Cash/sh | 3.21 | P/FCF | - | EPS past 3/5Y | - | ROIC | -129.74% | 52W Low | 4.82 215.15% | Perf 3Y | 59.39% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 6.51% 5.69% | Perf 5Y | -55.86% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -34.78% | Oper. Margin | 0.00% | ATR (14) | 0.85 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.30 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 60.91 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.30 | EPS Q/Q | 5.26% | SMA20 | 7.71% | Beta | 2.50 | Target Price | 18.63 |
| Payout | 0.00% | Debt/Eq | 0.20 | Sales Q/Q | - | SMA50 | 14.77% | Rel Volume | 1.03 | Prev Close | 15.00 |
| Employees | 156 | LT Debt/Eq | -0.02 | Earnings | Nov 03 | SMA200 | 58.63% | Avg Volume | 3.45M | Price | 15.19 |
| IPO Date | Sep 18, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 7.25% - | Net Debt/EBITDA | 0.97 | Volume | 3,565,958 | Change | 1.27% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-27-26 | Initiated | Wells Fargo | Equal Weight | $13 |
| Jul-20-26 | Reiterated | B.Riley Financial | $17 | |
| Jul-08-26 | Upgrade | Evercore ISI Group | In Line → Outperform | |
| Jul-07-26 | Reiterated | Stifel Nicolaus | $21 | |
| Jul-07-26 | Reiterated | Compass Point | $15 → $25 | |
| May-15-26 | Reiterated | Maxim Group | Buy | $20 |
| May-14-26 | Reiterated | Morgan Stanley | Overweight | $18 → $17 |
| May-07-26 | Initiated | UBS | $17 → $18 | |
| May-03-26 | Initiated | Jefferies | Buy | $18 |
| Apr-24-26 | Initiated | B. Riley | Buy | $17 |
Latest News· Times ET
Sep-17-26
Sep-17-2611:18AM
Sep-16-26
Sep-16-2610:31AM
02:30AM
Sep-15-26
Sep-15-2602:30AM
01:01AM
Sep-11-26
Sep-11-2612:10PM
Sep-10-26
Sep-10-2604:00AM
02:41AM
02:35AM
02:30AM
Sep-09-26
08:32AM
Compass Pathways stock rises as 52-week data show lasting depression reliefproactiveinvestors.com
02:30AM
Sep-08-26
Sep-08-2602:30AM
Sep-03-26
Sep-03-2612:30PM
Company
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 61 | 59 | 49 | — | — | — | — | — | |
| Research and Development | 118 | 119 | 88 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -179 | -178 | -137 | — | — | — | — | — | |
| Interest Expense | 5 | 4 | 2 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -107 | 29 | 21 | — | — | — | — | — | |
| Net Income Before Taxes | -290 | -154 | -118 | — | — | — | — | — | |
| Income Taxes | -2 | 2 | 1 | — | — | — | — | — | |
| Consolidated Net Income | -288 | -155 | -118 | — | — | — | — | — | |
| Net Income From Continuing Operations | -288 | -155 | -118 | — | — | — | — | — | |
| Net Income | -288 | -155 | -118 | — | — | — | — | — | |
| EPS (Recurring) | -3.08 | -2.30 | -2.32 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.08 | -2.30 | -2.32 | — | — | — | — | — | |
| EPS (Diluted) | -3.08 | -2.30 | -2.32 | — | — | — | — | — | |
| EBITDA | -286 | -149 | -115 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 94 | 67 | 51 | — | — | — | — | — | |
| Market Capitalization | 649 | 253 | 446 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Malievskaia Ekaterina | 10% Owner | Oct 24 '24 | Sale | 0.00 | 1,553,130 | 0 | 3,152,848 | Oct 25 |
| Goldsmith George Jay | 10% Owner | Oct 24 '24 | Sale | 0.00 | 1,553,130 | 0 | 3,152,848 | Oct 25 |
| ATAI Life Sciences N.V. | 10% Owner | Sep 26 '24 | Sale | 6.05 | 2,660,000 | 16,093,000 | 6,905,774 | Sep 27 |
| Goldsmith George Jay | 10% Owner | May 21 '24 | Sale | 7.91 | 17,800 | 140,758 | 3,929,413 | May 22 |
| Malievskaia Ekaterina | 10% Owner | May 21 '24 | Sale | 7.91 | 17,800 | 140,758 | 3,929,413 | May 22 |
| Goldsmith George Jay | 10% Owner | May 20 '24 | Sale | 7.89 | 13,407 | 105,808 | 3,938,313 | May 22 |
| Malievskaia Ekaterina | 10% Owner | May 20 '24 | Sale | 7.89 | 13,407 | 105,808 | 3,938,313 | May 22 |
| Goldsmith George Jay | 10% Owner | May 03 '24 | Sale | 8.82 | 37,523 | 330,904 | 3,945,017 | May 06 |
| Malievskaia Ekaterina | 10% Owner | May 03 '24 | Sale | 8.82 | 37,523 | 330,904 | 3,945,017 | May 06 |
| Goldsmith George Jay | 10% Owner | May 02 '24 | Sale | 8.29 | 19,243 | 159,528 | 3,963,778 | May 06 |
| Malievskaia Ekaterina | 10% Owner | May 02 '24 | Sale | 8.29 | 19,243 | 159,528 | 3,963,778 | May 06 |
| Goldsmith George Jay | 10% Owner | Apr 17 '24 | Sale | 8.78 | 21,700 | 190,614 | 3,973,400 | Apr 18 |
| Malievskaia Ekaterina | 10% Owner | Apr 17 '24 | Sale | 8.78 | 21,700 | 190,614 | 3,973,400 | Apr 18 |
| Malievskaia Ekaterina | 10% Owner | Apr 16 '24 | Sale | 8.53 | 47,761 | 407,349 | 3,984,250 | Apr 18 |
| Goldsmith George Jay | 10% Owner | Apr 16 '24 | Sale | 8.53 | 47,761 | 407,349 | 3,984,250 | Apr 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.